| Armand John Wolff, MD | |
|
226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610-2826 | |
| (203) 384-3394 | |
| (203) 384-3829 |
| Full Name | Armand John Wolff |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 30 Years |
| Location | 226 Mill Hill Ave, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093719700 | NPI | - | NPPES |
| 0297952 | Medicaid | IA | |
| 110246642 | Other | IA | RAILROAD MEDICARE |
| 110246642 | Other | NE | RAILROAD MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Group Inc | 1254233836 | 1251 |
News Archive
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.
A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.
Despite international praise for Ghana's successful economic growth and its "reputation as a beacon of democracy in Africa," "4,000 women die every year and over 200,000 are disabled due to pregnancy-related complications," Kwesi Owusu, executive producer of the Maternal Health Channel television series, writes in a CNN opinion piece.
Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.
A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.
Despite international praise for Ghana's successful economic growth and its "reputation as a beacon of democracy in Africa," "4,000 women die every year and over 200,000 are disabled due to pregnancy-related complications," Kwesi Owusu, executive producer of the Maternal Health Channel television series, writes in a CNN opinion piece.
Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Armand John Wolff, MD Po Box 415126, Mill Hill Medical Consultants, Inc., Boston, MA 02241-0001 Ph: (203) 384-3394 | Armand John Wolff, MD 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610-2826 Ph: (203) 384-3394 |
News Archive
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.
A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.
Despite international praise for Ghana's successful economic growth and its "reputation as a beacon of democracy in Africa," "4,000 women die every year and over 200,000 are disabled due to pregnancy-related complications," Kwesi Owusu, executive producer of the Maternal Health Channel television series, writes in a CNN opinion piece.
Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.
Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.
› Verified 5 days ago
Mitchell Andrew Fogel, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 900 Madison Ave, Suite 209, Bridgeport, CT 06606 Phone: 203-335-0195 Fax: 203-335-7293 | |
Christian Heineken, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3180 Main St, Suite 301, Bridgeport, CT 06606 Phone: 203-373-9100 Fax: 203-365-8492 | |
Pasquale Masone, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3180 Main St, Suite 301, Bridgeport, CT 06606 Phone: 203-373-9100 Fax: 203-365-8492 | |
Kevin B Panzer, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1381 Reservoir Ave., Bridgeport, CT 06606 Phone: 203-371-5197 | |
Ms. Lucia Plichtova, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 267 Grant Street, Bridgeport, CT 06610 Phone: 203-384-3792 | |
Hilda Daureen Kyotakoze, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4920 Main St Fl 2, Bridgeport, CT 06606 Phone: 203-371-2986 | |
Karen A Hutchinson, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610 Phone: 203-384-3873 Fax: 203-384-3829 |